Last reviewed · How we verify
Clover Biopharmaceuticals AUS Pty — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
3 Phase 3
1 Phase 2
8 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| AREXVY | AREXVY | marketed | Other | |||
| CoronaVac Vaccine | CoronaVac Vaccine | phase 3 | Inactivated viral vaccine | SARS-CoV-2 spike protein and other viral antigens | Immunology / Infectious Disease | |
| Comirnaty Vaccine | Comirnaty Vaccine | phase 3 | mRNA vaccine | SARS-CoV-2 spike protein (S protein) | Immunology / Infectious Disease | |
| Vaxzevria Vaccine | Vaxzevria Vaccine | phase 3 | Immunology |
Therapeutic area mix
- Immunology / Infectious Disease · 2
- Immunology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Pfizer · 2 shared drug classes
- Arcturus Therapeutics, Inc. · 1 shared drug class
- CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 shared drug class
- Bharat Biotech International Limited · 1 shared drug class
- BioNTech SE · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- AJ Vaccines A/S · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Clover Biopharmaceuticals AUS Pty:
- Clover Biopharmaceuticals AUS Pty pipeline updates — RSS
- Clover Biopharmaceuticals AUS Pty pipeline updates — Atom
- Clover Biopharmaceuticals AUS Pty pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Clover Biopharmaceuticals AUS Pty — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clover-biopharmaceuticals-aus-pty. Accessed 2026-05-16.